Last reviewed · How we verify
Furmonertinib Mesilate Tablets
Furmonertinib is a third-generation EGFR tyrosine kinase inhibitor that irreversibly binds to and inhibits mutant EGFR, including T790M resistance mutations.
Furmonertinib is a third-generation EGFR tyrosine kinase inhibitor that irreversibly binds to and inhibits mutant EGFR, including T790M resistance mutations. Used for Non-small cell lung cancer with EGFR mutations, including T790M resistance mutations.
At a glance
| Generic name | Furmonertinib Mesilate Tablets |
|---|---|
| Also known as | AST2818 |
| Sponsor | Allist Pharmaceuticals, Inc. |
| Drug class | Third-generation EGFR tyrosine kinase inhibitor |
| Target | EGFR (epidermal growth factor receptor) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Furmonertinib selectively targets epidermal growth factor receptor (EGFR) mutations commonly found in non-small cell lung cancer, particularly overcoming resistance mechanisms like the T790M mutation that render first and second-generation EGFR inhibitors ineffective. By irreversibly binding to the ATP-binding pocket of mutant EGFR, it suppresses downstream signaling pathways that drive cancer cell proliferation and survival.
Approved indications
- Non-small cell lung cancer with EGFR mutations, including T790M resistance mutations
Common side effects
- Diarrhea
- Rash
- Nausea
- Vomiting
- Fatigue
Key clinical trials
- A Study Evaluating Furmonertinib Plus Platinum-based Doublet Chemotherapy Versus Osimertinib in Patients With Epidermal Growth Factor Receptor (EGFR) Sensitizing Mutation-Positive Non-squamous Non-Small Cell Lung Cancer (NSCLC) and Brain Metastases (PHASE3)
- A Study of YL202 in Combination With Other Anti-tumor Therapies in Patients With Advanced Solid Tumors (PHASE1, PHASE2)
- A Phase Ⅱ Study of RC108 in Combination With Furmonertinib for the First-line Treatment of EGFR-Mutated Combined MET-Positive Unresectable Locally Advanced or Recurrent Metastatic NSCLC (PHASE2)
- To Evaluate the Efficacy and Safety of Anlotinib Combined With Furmonertinib Mesylate in Lung Cancer (PHASE2)
- Evaluation of JSKN016 Combination Therapy in Subjects with NSCLC (PHASE1)
- An Observational Study of Furmonertinib for EGFR Mutation-positive NSCLC Patients With Brain Metastasis
- A Study of Furmonertinib Combined With Chemotherapy in the Treatment of NSCLC With Leptomeningeal Metastasis (PHASE2)
- Furmonertinib in Patients With Leptomeningeal Metastases Associated With EGFR Mutated NSCLC (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Furmonertinib Mesilate Tablets CI brief — competitive landscape report
- Furmonertinib Mesilate Tablets updates RSS · CI watch RSS
- Allist Pharmaceuticals, Inc. portfolio CI